

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10595858
	Filing Date		2006-07-11
	First Named Inventor	Takashi Yoshinaga	
	Art Unit	1646	
	Examiner Name	N. S. Basi	
	Attorney Docket Number	09857/0204372-US0	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10595858
Filing Date		2006-07-11
First Named Inventor	Takashi Yoshinaga	
Art Unit	1646	
Examiner Name	N. S. Basi	
Attorney Docket Number	09857/0204372-US0	

1	MORGENSTERN, J. P. et al. "Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line." Nucleic Acids Research, Oxford University Press, Surrey GB, vol. 19, no. 12, 1990, pg. 3587-3596.	<input type="checkbox"/>
2	"ViraPower™ Lentiviral Expression System." 2002, Invitrogen Corporation. (http://www.invitrogen.com/content/sfs/brochures/710_021387_viraPowerAnnounc.pdf).	<input type="checkbox"/>
3	SCHROEDER, KIRK S. "An Interview with Kirk S. Schroeder, President, Essen Instruments." Assay and Drug Development Technologies. Nov. 2002, vol. 1, no 1, pt 1. November 2002 (2002-11) pages 3-8.	<input type="checkbox"/>
4	BENNETT, P. B. et al. "Trends in Ion-Channel Drug Discovery: Advances in Screening Technologies." Trends in Biotechnology, Elsevier Publications, Cambridge, GB, vol. 21, no. 12. October 28, 2003 (pages 563-569).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.